Effects of insulin-like growth factor-I administration on in vivo regulation of urea synthesis in normal subjects and patients with cirrhosis

Liver International

Volumn 31, Issue 1, 2011, Pages 132-137

  Sandahl, Thomas D ^a   Aagaard, Niels K ^a   Thomsen, Karen L ^a   Grøfte, Thorbjørn ^a   Greisen, Jacob ^a   Christiansen, Jens S ^a   Vilstrup, Hendrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cirrhosis; Glucagon; Liver; Metabolism; Nitrogen

Indexed keywords

ALANINE; ALPHA AMINO ACID; NITROGEN; SODIUM CHLORIDE; SOMATOMEDIN C; UREA;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER FUNCTION; LIVER METABOLISM; MALE; RANDOMIZED CONTROLLED TRIAL; UREA CYCLE; URINARY EXCRETION;

ADULT; ALANINE; CROSS-OVER STUDIES; DENMARK; FEMALE; GLUCAGON; HUMAN GROWTH HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PLACEBO EFFECT; TIME FACTORS; TREATMENT OUTCOME; UREA;

EID: 78650136831     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02362.x     Document Type: Article

References (22)

1. Grøfte T, Wolthers T, Jensen SA, et al. Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats. Hepatology 1997; 25: 964-9.
2. Wolthers T, Grøfte T, Jørgensen JOL, et al. Effects of growth hormone (GH) administration on functional hepatic nitrogen clearance: studies in normal subjects and GH-deficient patients. J Clin Endocrinol Metab 1994; 78: 1220-4.
3. Wolthers T, Grøfte T, Møller N, Vilstrup H, Jørgensen JOL. Effects of long-term growth hormone (GH) and triiodothyronine (T3) administration on functional hepatic nitrogen clearance in normal man. J Hepatol 1996; 24: 313-9.
4. Donaghy A, Ross R, Gimson A, et al. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995; 21: 680-8.
5. Vilstrup H. Synthesis of urea after stimulation with amino acids: relation to liver function. Gut 1980; 21: 990-5.
6. Sobrevals L, Rodriguez C, Romero-Trevejo JL, et al. Insulin-like growth factor i gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010; 51: 912-21.
7. Conchillo M, De Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43: 630-6.
8. Nunez M, Urdaneta E, Santidrian S. Effect of insulin-like growth factor-I on nitrogen balance and intestinal galactose transport in rats with moderate liver cirrhosis. Br J Nutr 2003; 90: 929-37.
9. Vilstrup H. On urea synthesis - regulation in vivo. Dan Med Bull 1989; 36: 415-29.
10. Fawcett JK, Scott JE. A rapid and precise method for the determination of urea. J Clin Pathol 1960; 13: 156-9.
11. Goodwin JF. Spectrophotometric quantitation of plasma and urinary amino nitrogen with fluorodinitrobenzene. Stand Methods Clin Chem 1970; 6: 89-98.
12. Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995; 5: 169-76.
13. Frystyk J. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348: 185-91.
14. Krassas GE, Pontikides N, Kaltsas T, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88: 132-5.
15. Vilstrup H, Hansen BA, Almdal TP. Glucagon increases hepatic efficacy for urea synthesis. J Hepatol 1990; 10: 46-50.
16. Chen JW, Højlund K, Beck-Nielsen H, et al. Free rather than total circulating insulin-like growth factor-I determines the feedback on growth hormone release in normal subjects. J Clin Endocrinol Metab 2005; 90: 366-71.
17. Shmueli E, Miell JP, Stewart M, Alberti KGMM, Record CO. High insulin-like growth factor binding protein 1 levels in cirrhosis: link with insulin resistance. Hepatology 1996; 24: 127-33.
18. Donaghy A, Ross R, Wicks C, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology 1997; 113: 1617-22.
19. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
20. Marchesini G, Bua V, Brunori A, et al. Galactose elimination capacity and liver volume in aging man. Hepatology 1988; 8: 1079-83.
21. Marchesini G, Bianchi GP, Fabbri A, et al. Synthesis of urea after a protein-rich meal in normal man in relation to ageing. Age Ageing 1990; 19: 4-10.
22. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-601.